Savara Inc. Class Action Lawsuit
Analysis based on 9 articles · First reported Sep 18, 2025 · Last updated Oct 16, 2025
The market is impacted by the class action lawsuit against Savara, as it suggests potential financial liabilities and a negative outlook for Savara's stock. Investors who purchased Savara shares during the class period may experience losses, while the legal action could lead to a recovery for affected shareholders.
Savara, a publicly traded company, is facing a class action lawsuit initiated by The Gross Law Firm on behalf of its shareholders. The lawsuit alleges that Savara issued materially false and/or misleading statements and failed to disclose critical information regarding its drug, MOLBREEVI BLA, intended for pulmonary alveolar proteinosis. Specifically, the complaint claims that MOLBREEVI BLA lacked sufficient information concerning its chemistry, manufacturing, and controls, making United States — Food and Drug Administration approval unlikely in its current form. This delay in regulatory approval increased the probability that Savara would need to raise additional capital, contrary to its representations to investors. The class period for the lawsuit is from March 4, 2024, to May 23, 2025, with a deadline for shareholders to seek lead plaintiff appointment by November 7, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard